Mobile

A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerabitlity, and Efficacy of Telcagepant (MK-0974) for prevention of Menstrually Related...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-019288-13

A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerabitlity, and Efficacy of Telcagepant (MK-0974) for prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

1. To evaluate the efficacy of telcagepant 140 mg once daily for 7-days per month compared to placebo for the prevention of migraine during the study period in female patients with menstruelly related migraine or pure menstrual migraine. 2. To examine the tolerability and safety of telcagepant 140 mg once daily for 7-days per month for the preventive treatment of migraine in female patients with episodic migraine.

Critère d'inclusion

  • Migraine

Liens